Neil Clark of Destiny Pharma discusses XF-73’s significant Phase 2 data published in a peer reviewed journal & potential upside.
If you find this podcast useful please give it a rating and review on iTunes by clicking here
Neil Clark, CEO of discusses XF-73’s Phase 2 data published in peer reviewed journal and the potential upside for the share price. Three brokers price targets currently stand at: Equity Development = 267p, Finncap = 285p, Shore Capital = 290p. Current share price = 31p.
The paper was published by Dr. Julie Mangino (Professor Emeritus, Division of Infectious Diseases, at The Ohio State University, US) who is the lead author and a member of the Data Safety Monitoring Committee for the clinical trial.
It highlights the following key results:
ü Achieved the study primary endpoint: XF-73 showed a 99.5% reduction in S. aureus bacterial nasal carriage, which is a clinically relevant reduction in nasal carriage. This equates to a reduced nasal burden of S. aureus in patients undergoing open heart surgery by 2.5 log (CFU/ml) in the 24 hours immediately before surgery, a highly statistically significant result, (p<0.0001)
ü 83.7% of XF-73 nasal gel treated patients were completely decolonised of nasal S. aureus or exhibited a ≥99% reduction one hour ahead of surgery compared to just 25% in the placebo group
ü These positive results were achieved with just 3 doses of XF-73 nasal gel in the 24 hours before the surgical incision
ü XF-73 decolonisation of S. aureus was maintained throughout the perioperative period, which is considered to be when the risk of infection is highest
Craig discusses their interim results, fact sheet and subjects covered on a recnt webinar.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.